Pharma Sector

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

DGFT's floor prices on select bulk drugs aim to curb Chinese dumping, support PLI-backed manufacturers and lift domestic offtake, though capped medicine prices may limit cost pass-through

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a US FDA filing expected soon

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Exporters like Sun Pharma, Dr Reddy's may see 7-8% revenue lift, yet margins pressured by high raw material import costs

The UK has sealed a deal securing a 0 per cent tariff rate for all UK medicines exported to the US for at least 3 years, officials said Monday, in return for the UK spending more on new medicines. Under the deal, announced by officials on both sides, the United States government agreed to exempt UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from import taxes. The Trump administration said that in return, UK drugs firms committed to invest more in the US and create more jobs. As part of the deal, the UK government said it will invest around 25 per cent more in new and effective treatments the first major increase in such spending in over two decades. Both sides hailed the deal as a win. This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives, Science and Technology Secretary Liz Kendall said. US Health Secretary Robert F. Kennedy Jr.

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

Following the Chhindwara cough syrup tragedy, a CDSCO committee has advised consultations to phase out high-risk solvents in oral formulations

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

Industry representatives argue that global acceptance of Indian Pharmacopoeia could significantly reduce export costs and make Indian drugs more affordable to developing nations

Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

The initial public offer of Sudeep Pharma Ltd received 5.09 times subscription on the second day of bidding on Monday. The IPO received bids for 5,37,83,650 shares against 1,05,64,926 shares on offer, according to NSE data. The category for non-institutional investors fetched 12 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 4.96 times. The Qualified Institutional Buyers (QIBs) portion received 13 per cent subscription. Sudeep Pharma on Thursday said it has mobilised Rs 268.5 crore from anchor investors. The Rs 895 crore initial public offering (IPO) will conclude on Tuesday. The price band has been fixed at Rs 563-593 per equity share. The IPO has a fresh issue of equity shares worth Rs 95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to Rs 800 crore, by the promoters. Proceeds from the fresh issue to the tune of Rs 75.81 crore will be used for capital expenditure towards the procurement of machinery for it

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.